Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Antisense Therapeutics Ltd. (OTC: ATHJF).

Full DD Report for ATHJF

You must become a subscriber to view this report.


Recent News from (OTC: ATHJF)

ATL1103 Phase II Trial Results Published in the European Journal of Endocrinology
MELBOURNE, AUSTRALIA / ACCESSWIRE / May 23, 2018 / Antisense Therapeutics (the "Company" or "ANP") (ASX: ANP; OTC PINK: ATHJF) is pleased to announce the acceptance for publication of previously reported positive Phase II clinical trial data on ATL1103 (atesidorsen) in the leading peer-revie...
Source: ACCESSWIRE
Date: May, 23 2018 12:45
3 Things In Biotech, March 2: Shire Pushes, Acceleron Shines, And Antisense Goes On
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech" a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Shir...
Source: SeekingAlpha
Date: March, 03 2018 08:00
Approval Received for Phase II Trial of ATL1102 in Duchenne Muscular Dystrophy
MELBOURNE, AUSTRALIA / ACCESSWIRE / February 28, 2018 / Antisense Therapeutics ("ANP" or the "Company") (ASX: ANP; OTC PINK: ATHJF) is pleased to advise that the Company has received approval from the Royal Children's Hospital (RCH), Melbourne Human Research Ethics Committee, to undertake a ...
Source: ACCESSWIRE
Date: February, 28 2018 11:06

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-11N/A0.035N/AN/A0
2018-12-10N/A0.035N/AN/A0
2018-12-07N/A0.035N/AN/A0
2018-12-06N/A0.035N/AN/A0
2018-12-05N/A0.035N/AN/A0

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-10-1950,00050,000100.0000Short
2018-09-112,0002,000100.0000Short
2018-08-281,5001,500100.0000Short
2018-08-21100100100.0000Short
2018-07-301,0002,00050.0000Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ATHJF.


About Antisense Therapeutics Ltd. (OTC: ATHJF)

Logo for Antisense Therapeutics Ltd. (OTC: ATHJF)

Not available

 

Contact Information

 

 

Current Management

  • Mark Diamond / Managing Director, CEO

Current Share Structure

  • Market Cap: $3,026,019 - 03/16/2018
  • Issue and Outstanding: 144,096,128 - 02/05/2014

 



Daily Technical Chart for (OTC: ATHJF)

Daily Technical Chart for (OTC: ATHJF)


Stay tuned for daily updates and more on (OTC: ATHJF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: ATHJF)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ATHJF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ATHJF and does not buy, sell, or trade any shares of ATHJF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/